{
    "organizations": [],
    "uuid": "ab838b8ded9bc4dc44344b258a95546655501d78",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-revance-reports-qtrly-net-loss-per/brief-revance-reports-qtrly-net-loss-per-share-attributable-to-common-stockholders-1-14-idUSASB0C83M",
    "ord_in_thread": 0,
    "title": "BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Revance Therapeutics Inc:\n* REVANCE RELEASES FOURTH QUARTER AND FULL YEAR 2017 RESULTS\n* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​\n* REVANCE THERAPEUTICS INC - QTRLY BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $1.14\n* REVANCE THERAPEUTICS INC - ‍EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-01T05:57:00.000+02:00",
    "crawled": "2018-03-01T21:15:08.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "revance",
        "therapeutic",
        "inc",
        "revance",
        "release",
        "fourth",
        "quarter",
        "full",
        "year",
        "result",
        "revance",
        "therapeutic",
        "inc",
        "financial",
        "guidance",
        "provided",
        "january",
        "revance",
        "therapeutic",
        "inc",
        "qtrly",
        "basic",
        "diluted",
        "net",
        "loss",
        "per",
        "share",
        "attributable",
        "common",
        "stockholder",
        "revance",
        "therapeutic",
        "inc",
        "cash",
        "burn",
        "range",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}